Therapy for overactive detrusor using propiverine;Therapie der detrusorhyperaktivität mit propiverin

Urologe - Ausgabe A

Volumn 44, Issue 4, 2005, Pages 382-386

  Alloussi, S ^a   Goepel, M ^b   Richter, A E ^c   Eberhardt, R ^d   Zwingers, T ^d   Brunjes R ^e  

^a Urologische Abteilung   (Germany)

^b Klin F Urologie Kinderurologie K   (Germany)

^c Urologische Praxis ^*  (Germany)

^d Pharmalog Inst F Klin Forsch G   (Germany)

^e APOGEPHA Arzneimittel GmbH   (Germany)

Author keywords

Detrusor overactivity; Efficacy; Post marketing surveillance; Propiverine; Tolerability

Indexed keywords

PROPIVERINE;

ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; HUMAN; MEDICAL PRACTICE; MICTURITION; OVERACTIVE BLADDER; PATIENT CARE; POSTMARKETING SURVEILLANCE; RISK BENEFIT ANALYSIS; SIDE EFFECT; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZILATES; CAUSALITY; COMORBIDITY; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MUSCLE HYPERTONIA; PREVALENCE; PRODUCT SURVEILLANCE, POSTMARKETING; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 18844437797     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-005-0774-z     Document Type: Article

References (13)

1. Abrams P, Cardozo L, Fall M et al. (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 21: 167-178
2. Alloussi S, Schönberger B, Mürtz G, Schubert G, Siegert J (2000) Behandlung des Urge-Syndroms mit Propiverin in der therapeutischen Praxis. Urologe B 40: 367-373
3. nd Annual Meeting, 28-30 August
4. De Geeter P (1993) Die Behandlung von Blasenfunktionsstörungen mit Oxybutynin in der urologischen Praxis - Ergebnisse einer Anwendungsbeobachtung 1990/91. Kontinenz 5: 201-204
5. Dorschner W, Stolzenburg JU, Griebenow R et al. (2000) Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur Urol 37: 702-708
6. Höfner K (2000) Medikamentöse Therapie der Instabilen Blase - Anwendungsbeobachtung mit Tolterodin bei 16.000 Patienten. Urologe B 40: 161-165
7. Hönig R, Eberhardt R, Kori-Lindner C, Langen M (Hrsg) (1998) Anwendungsbeobachtung - Qualitätsstandards, praktische Durchführung, Beitrag zur Arzneimittelsicherheit und Nachzulassung. Habrich, Berlin
8. Jünemann KP, Halaska M, Rittstein T, Brünjes R (2003) Propiverine vs. Tolterodine - efficacy and tolerability in patients with detrusor overactivity. Neurourol Urodyn 22/5
9. Madersbacher H, Halaska M, Voigt R, Alloussi S, Höfner K (1999) A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84: 646-651
10. Madersbacher H, Mürtz G (2001) Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 19: 324-335
11. Madersbacher H, Jähnig L, Rettig K (1995) Reizblasensymptomatik und Harndranginkontinenz - Wirksame Therapie mit Spasmo-lyt®-Dragées. Allgemeinarzt S 501-503
12. Stöhrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K (1999) Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord 37: 196-200
13. nd Annual Meeting, 28-30 August